GeoVax Labs is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor cancers using vector vaccine platforms. Co.'s product pipeline includes human clinical trials in COVID-19 vaccine and a theraphy against head and neck cancer. Additional research and development programs include preventive vaccines against Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Co.'s cancer therapy programs are Gedeptin® and MUC1-based Immunotherapy. The GOVX average annual return since 2020 is shown above.
The Average Annual Return on the GOVX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GOVX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GOVX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|